Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.

about

Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.

Item

http://www.wikidata.org/entity/Q39156749

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@en

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@nl

type

Item

label

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@en

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@nl

prefLabel

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@en

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@nl

P1476

Synthesis, antitumor evaluatio ...... or receptor (EGFR) inhibitors.

@en

P2093

Geng-Jie Xu

http://www.w3.org/2001/XMLSchema#string

Guo-Wu Rao

http://www.w3.org/2001/XMLSchema#string

Hai-Bo Li

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Xu-Liang Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

ERBB receptors and cancer: the complexity of targeted inhibitors

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.

Discovery of selective irreversible inhibitors for EGFR-T790M.

Targeting the EGFR pathway for cancer therapy.

Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.

Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.

P304

928-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201300120

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23640754

http://www.w3.org/2001/XMLSchema#string